Pharmaceutical intermediates
Fruquintinib Intermediates
5 pharmaceutical intermediates for Fruquintinib. Indication: Endometrial cancer; Colorectal cancer.
About Fruquintinib
- Originator
- Hutchison Medipharma Ltd
- Indication
- Endometrial cancer; Colorectal cancer
- Approved Date
- 11/08/2023
- DS/DP
- 05/09/2028
Available intermediates
5 intermediates currently listed for Fruquintinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 6,7-Dimethoxy-3,4-dihydroquinazoline -4-one | 13794-72-4 | / | / |
| 4-Chloro-6,7-dimethoxyquinazoline | 13790-39-1 | / | / |
| 6-methoxy-2-methylbenzofuran -3-carboxylic acid | 103986-33-0 | / | / |
| 6-Hydroxy-2-methylbenzofuran -3-carboxylic acid | 854515-52-9 | / | / |
| 6-Hydroxy-N-methyl-2-methyl-1-benzofuran-3-carboxamide | 638217-08-0 | / | / |
Building toward Fruquintinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →